Syrma Johari MedTech expands medical plastics manufacturing with new precision molding facility

Syrma Johari MedTech (SJML), a medical-device manufacturing company, has expanded its manufacturing footprint with the launch of a new medical plastics and precision molding facility, adding capabilities to support medical device, diagnostic and healthcare applications.

Spread across 1.29 lakh sq. ft., with 0.98 lakh sq. ft. currently developed and 0.31 lakh sq. ft. reserved for future expansion, the facility adds dedicated capabilities in injection molding, plastics extrusion and stretch blow molding to SJML’s manufacturing platform. The expansion enables the company to address polymer-based components and consumables across varying geometries, material systems and production volumes.

The facility has been developed to respond to the role of engineered plastics in medical and diagnostic products. Polymer components used in housings, cartridges, containers, tubing, fluid-handling components and microfluidic assemblies require dimensional precision, material performance, repeatability, cleanliness and manufacturing consistency.

With 80T, 130T and 280T injection molding capabilities, a 30–80 kg/hr extrusion line and 2.5-litre PET stretch blow molding, the facility provides SJML with a processing platform for medical polymer applications. Secondary capabilities including screen printing, pad printing, laser printing and assembly further extend the processes that can be integrated within the manufacturing ecosystem.

The facility also incorporates ISO Class 7 and ISO Class 8 cleanroom environments for applications where particulate control, cleanliness and contamination management are required. Its material-processing capabilities cover thermoplastics, elastomers and engineering polymers, including PP, PE, PS, PC, TPEs, PA6, PA66 and glass-fibre-reinforced polymer systems, allowing material selection to be aligned with the functional and manufacturing requirements of individual applications.

The new facility is supported by SJML’s quality and regulatory framework for medical-device manufacturing. The company operates under an ISO 13485 Quality Management System, with manufacturing systems designed around US FDA regulatory requirements, processes aligned with MDSAP requirements and compliance with applicable CDSCO regulations.

Process and equipment qualification, including IQ, OQ and PQ, forms part of the manufacturing framework, alongside digital traceability, incoming and in-process inspection, final inspection, calibration and risk-based quality controls. Continuous improvement methodologies including CAPA, SPC, FMEA, Kaizen and Quality by Design further support process control, consistency and manufacturing reliability.

The addition of plastics manufacturing extends SJML’s medical manufacturing platform, bringing materials, tooling, processing, validation, quality and scale-up capabilities closer together within a single manufacturing ecosystem.

As medical-device and diagnostic architectures become increasingly sophisticated, the ability to develop and manufacture polymer components with control over material selection, precision, cleanliness and repeatability becomes part of the product development and manufacturing journey. SJML’s expanded capabilities are designed to support this transition from component development to repeatable and scalable production.

With the new facility, SJML further broadens the technologies and production requirements it can address across diagnostics, critical care, medical devices and associated consumables, reinforcing its role as a manufacturing partner for global companies developing and scaling healthcare products.

The expansion marks another step in SJML’s continued investment in manufacturing capabilities, with a focus on building a more integrated, scalable and quality-driven platform for the evolving needs of the global medical and healthcare industry.